Rationale and design to assess the efficacy and safety of HT047 in patients with acute ischemic stroke: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase II trial

Sung Hyuk Heo, Jungbin Song, Bum Joon Kim, Hocheol Kim, Dae-Il Chang, HT047 investigators, Sung Hyuk Heo, Jungbin Song, Bum Joon Kim, Hocheol Kim, Dae-Il Chang, HT047 investigators

Abstract

Background: Though several neuroprotective agents have been evaluated as potential treatments for acute ischemic stroke, none have demonstrated a definitive treatment efficacy, which remains elusive. HT047 is an herbal extract of Scutellaria baicalensis and Pueraria lobata, both of which have been widely used to treat ischemic stroke in traditional Korean medicine. The aims of this trial are to investigate whether HT047 can improve neurologic status, particularly motor function, in acute ischemic stroke patients, and to determine the safety of HT047.

Methods: A multicenter, double-blind, randomized, placebo-controlled, 3-arm parallel group, phase II trial will be conducted in patients who have had an acute ischemic stroke within the past 14 days. The participating patients must have a Fugl-Meyer assessment (FMA) motor score ≤55, with arm or leg weakness, and Korean version of the National Institutes of Health Stroke scale (K-NIHSS) score of ≥4 and ≤15. Seventy-eight participants will be randomized in a 1:1:1 ratio and given high-dose HT047 (750 mg 3 times a day), low-dose HT047 (500 mg 3 times a day), or a placebo for 12 weeks. The primary endpoint is the change in FMA motor score between baseline and week 12. Secondary endpoints are as follows: the change in FMA motor score at weeks 4 and 8 from baseline; the change in FMA motor score at weeks 4, 8, and 12 from baseline according to the timing of treatment initiation (either within 1 week, or 1-2 weeks), or according to the presence of prognostic risk factors (hypertension, diabetes, dyslipidemia, etc); the change in K-NIHSS and Korean versions of the modified Rankin scale (K-mRS) and the modified Barthel index at weeks 4 and 12 from baseline; and the proportion of subjects at week 12 with a K-NIHSS score of 0 to 2, or with K-mRS scores of 0, ≤1, and ≤2.

Discussion: This study is a 1st-in-human trial of HT047 to explore the efficacy and safety in acute ischemic stroke patients. The results will provide the appropriate dosage and evidence of therapeutic benefit of HT047 for stroke recovery.

Trial registration: ClinicalTrials.gov (NCT02828540) Registered July 11, 2016.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. Moretti A, Ferrari F, Villa RF. Neuroprotection for ischaemic stroke: current status and challenges. Pharmacol Ther 2015;146:23–34..
    1. Chen J, Venkat P, Zacharek A, et al. Neurorestorative therapy for stroke. Front Hum Neurosci 2014;8:382.
    1. Alvarez-Sabin J, Roman GC. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci 2013;3:1395–414..
    1. Sahota P, Savitz SI. Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics 2011;8:434–51..
    1. Fisher M. New approaches to neuroprotective drug development. Stroke 2011;42:S24–7..
    1. Raghavan A, Shah ZA. Withania somnifera: a pre-clinical study on neuroregenerative therapy for stroke. Neural Regen Res 2015;10:183–5..
    1. Aras AB, Guven M, Akman T, et al. Neuroprotective effects of daidzein on focal cerebral ischemia injury in rats. Neural Regen Res 2015;10:146–52..
    1. Gaire BP, Moon SK, Kim H. Scutellaria baicalensis in stroke management: nature's blessing in traditional Eastern medicine. Chin J Integr Med 2014;20:712–20..
    1. Liang W, Huang X, Chen W. The effects of baicalin and baicalein on cerebral ischemia: a review. Aging Dis 2017;8:850–67..
    1. Zhang Z, Lam TN, Zuo Z. Radix Puerariae: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2013;53:787–811..
    1. Haque Bhuiyan MM, Mohibbullah M, Hannan MA, et al. The neuritogenic and synaptogenic effects of the ethanolic extract of radix Puerariae in cultured rat hippocampal neurons. J Ethnopharmacol 2015;173:172–82..
    1. Cho H, Lee HY, Ahn DR, et al. Baicalein induces functional hypoxia-inducible factor-1alpha and angiogenesis. Mol Pharmacol 2008;74:70–81..
    1. Kim E, Woo MS, Qin L, et al. Daidzein augments cholesterol homeostasis via ApoE to promote functional recovery in chronic stroke. J Neurosci 2015;35:15113–26..
    1. Lim JS, Yoo M, Kwon HJ, et al. Wogonin induces differentiation and neurite outgrowth of neural precursor cells. Biochem Biophys Res Commun 2010;402:42–7..
    1. Wang P, Jeng CJ, Chien CL, et al. Signaling mechanisms of daidzein-induced axonal outgrowth in hippocampal neurons. Biochem Biophys Res Commun 2008;366:393–400..
    1. Wu XD, Wang C, Zhang ZY, et al. Puerarin attenuates cerebral damage by improving cerebral microcirculation in spontaneously hypertensive rats. Evid Based Complement Alternat Med 2014;2014:408501.
    1. Zhang K, Lu J, Mori T, et al. Baicalin increases VEGF expression and angiogenesis by activating the ERRα/PGC-1α pathway. Cardiovasc Res 2011;89:426–35..
    1. Zhuang PW, Cui GZ, Zhang YJ, et al. Baicalin regulates neuronal fate decision in neural stem/progenitor cells and stimulates hippocampal neurogenesis in adult rats. CNS Neurosci Ther 2013;19:154–62..
    1. Fugl-Meyer AR, Jaasko L, Leyman I, et al. The post-stroke hemiplegic patient. 1. A method for evaluation of physical performance. Scand J Rehabil Med 1975;7:13–31..
    1. Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011;10:123–30..
    1. O’Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467–77..
    1. Kim JS. tPA helpers in the treatment of acute ischemic stroke: are they ready for clinical use? J Stroke 2019;21:160–74..
    1. Gong X, Sucher NJ. Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Trends Pharmacol Sci 1999;20:191–6..
    1. Han SY, Hong ZY, Xie YH, et al. Therapeutic effect of Chinese herbal medicines for post stroke recovery: a traditional and network meta-analysis. Medicine 2017;96:e8830.
    1. Gladstone DJ, Danells CJ, Black SE. The fugl-meyer assessment of motor recovery after stroke: a critical review of its measurement properties. Neurorehabil Neural Repair 2002;16:232–40..

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever